Recognition of non-operating expenses
The submitting company (Medrx Co.,Ltd.) and overseas subsidiaries (names not disclosed)
Financial statement items of overseas subsidiaries, foreign currency deposits, accounts payable, and the 35th Series of Stock Acquisition Rights with Exercise Price Adjustment Clauses
The foreign exchange loss arose from the translation of financial statement items of overseas subsidiaries, the translation of foreign currency deposits, and the settlement of accounts payable, among other matters. The non-operating administrative fees were paid to law firms and others in connection with the issuance of the 35th Series of Stock Acquisition Rights with Exercise Price Adjustment Clauses.
¥6 million in foreign exchange losses and ¥6 million in non-operating administrative fees, both recorded as non-operating expenses
Cumulative period of the second quarter of the fiscal year ending December 2026 (1 January 2026 to 30 June 2026)
For the impact on the Medrx Group's results for the second quarter of the fiscal year ending December 2026, please refer to the "Summary of Financial Results for the Second Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)" released today (7 August 2026).
For the impact on the Medrx Group's results for the second quarter of the fiscal year ending December 2026, please refer to the "Summary of Financial Results for the Second Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)" released today (7 August 2026).
| Item | Details |
|---|---|
| Event name | Recognition of non-operating expenses |
| Subject Entity | The submitting company (Medrx Co.,Ltd.) and overseas subsidiaries (names not disclosed) |
| Target Locations / Products | Financial statement items of overseas subsidiaries, foreign currency deposits, accounts payable, and the 35th Series of Stock Acquisition Rights with Exercise Price Adjustment Clauses |
| Cause | The foreign exchange loss arose from the translation of financial statement items of overseas subsidiaries, the translation of foreign currency deposits, and the settlement of accounts payable, among other matters. The non-operating administrative fees were paid to law firms and others in connection with the issuance of the 35th Series of Stock Acquisition Rights with Exercise Price Adjustment Clauses. |
| Amount of Impact on Business Performance | ¥6 million in foreign exchange losses and ¥6 million in non-operating administrative fees, both recorded as non-operating expenses |
| Accounting period in which recognized | Cumulative period of the second quarter of the fiscal year ending December 2026 (1 January 2026 to 30 June 2026) |
| Impact on Earnings Forecast | For the impact on the Medrx Group's results for the second quarter of the fiscal year ending December 2026, please refer to the "Summary of Financial Results for the Second Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)" released today (7 August 2026). |
| Outlook | For the impact on the Medrx Group's results for the second quarter of the fiscal year ending December 2026, please refer to the "Summary of Financial Results for the Second Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)" released today (7 August 2026). |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The foreign exchange loss arose from the translation of financial statement items of overseas subsidiaries, the translation of foreign currency deposits, and the settlement of accounts payable, among other matters. The non-operating administrative fees were paid to law firms and others in connection with the issuance of the 35th Series of Stock Acquisition Rights with Exercise Price Adjustment Clauses.